CL2024001180A1 - Complejo polipeptídico activable - Google Patents

Complejo polipeptídico activable

Info

Publication number
CL2024001180A1
CL2024001180A1 CL2024001180A CL2024001180A CL2024001180A1 CL 2024001180 A1 CL2024001180 A1 CL 2024001180A1 CL 2024001180 A CL2024001180 A CL 2024001180A CL 2024001180 A CL2024001180 A CL 2024001180A CL 2024001180 A1 CL2024001180 A1 CL 2024001180A1
Authority
CL
Chile
Prior art keywords
polypeptide complex
activatable polypeptide
activatable
hbpc
preparing
Prior art date
Application number
CL2024001180A
Other languages
English (en)
Spanish (es)
Inventor
M Boustany Leila
M Paidhungat Madan
Anne Mariano Fox Ellaine
Mitra Sayantan
Michael Kavanaugh W
Briante Raffaella
Leann Stevens Jennitte
Original Assignee
Cytomx Therapeutics Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc, Amgen Inc filed Critical Cytomx Therapeutics Inc
Publication of CL2024001180A1 publication Critical patent/CL2024001180A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2024001180A 2021-10-15 2024-04-15 Complejo polipeptídico activable CL2024001180A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256410P 2021-10-15 2021-10-15
US202263370895P 2022-08-09 2022-08-09

Publications (1)

Publication Number Publication Date
CL2024001180A1 true CL2024001180A1 (es) 2024-10-04

Family

ID=84331755

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001180A CL2024001180A1 (es) 2021-10-15 2024-04-15 Complejo polipeptídico activable

Country Status (17)

Country Link
US (1) US20230183382A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539650A (cg-RX-API-DMAC7.html)
KR (1) KR20240115809A (cg-RX-API-DMAC7.html)
CN (1) CN118103405A (cg-RX-API-DMAC7.html)
AU (1) AU2022365116A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234609A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006111A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240204A (cg-RX-API-DMAC7.html)
IL (1) IL312145A (cg-RX-API-DMAC7.html)
JO (1) JOP20240086A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024004563A (cg-RX-API-DMAC7.html)
PE (1) PE20241343A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330611A (cg-RX-API-DMAC7.html)
UY (1) UY39984A (cg-RX-API-DMAC7.html)
WO (1) WO2023064927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4496816A1 (en) * 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Egfrviii及cd3抗體構築體
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP4126248A4 (en) * 2020-03-31 2024-07-10 Fred Hutchinson Cancer Center HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES

Also Published As

Publication number Publication date
JP2024539650A (ja) 2024-10-29
CN118103405A (zh) 2024-05-28
PE20241343A1 (es) 2024-07-03
US20230183382A1 (en) 2023-06-15
IL312145A (en) 2024-06-01
CO2024006111A2 (es) 2024-06-27
MX2024004563A (es) 2024-04-30
CR20240204A (es) 2024-09-13
EP4416180A1 (en) 2024-08-21
WO2023064927A9 (en) 2024-05-16
KR20240115809A (ko) 2024-07-26
WO2023064927A1 (en) 2023-04-20
CA3234609A1 (en) 2023-04-20
UY39984A (es) 2023-07-31
AU2022365116A1 (en) 2024-05-02
TW202330611A (zh) 2023-08-01
JOP20240086A1 (ar) 2024-04-14

Similar Documents

Publication Publication Date Title
CO2024006111A2 (es) Complejo polipeptídico activable
CL2024001178A1 (es) Complejo polipeptídico activable
MY199655A (en) Dll3-cd3 bispecific antibodies
PH12019500550A1 (en) Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
PH12020550408A1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
PE20211603A1 (es) Anticuerpos que se unen a cd3
PE20211778A1 (es) Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
MX2024006992A (es) Anticuerpos contra ligando 1 de muerte programada.
MX2018000344A (es) Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
MX342135B (es) Anticuerpos asimetricos, biespecificos y monoespecificos, y metodos para generar los mismos.
HK1218930A1 (zh) 新型多特异性结构
MA39266A (fr) Anticorps bispécifiques anti cd3epsilon et bcma
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
NZ715896A (en) Humanized or chimeric cd3 antibodies
EA201900443A1 (ru) Антитело к pd-l1 и его применение
AR114001A1 (es) Anticuerpos que se unen a hla- a2 / wt1
MX2020011588A (es) Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
MX2020012589A (es) Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos.
EP4268848A3 (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
MX2023008172A (es) Anticuerpo biespecifico de forma heterodimerica similar a la estructura del anticuerpo natural anti-pd-l1/anti-4-1bb y preparacion del mismo.
CL2024001075A1 (es) Administración subcutánea de anticuerpos acopladores a linfocitos t de unión a cd19
MY204320A (en) Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
MX2022001882A (es) Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.